CDK 4/6 inhibitors sensitize PIK3CA Mutant Breast Cancer to PI3K inhibitors

Activation of the phosphoinositide 3-kinase (PI3K) pathway occurs frequently in breast cancer. However, clinical results of single-agent PI3K inhibitors have been modest to date. A combinatorial drug screen on multiple PIK3CA mutant cancers with decreased sensitivity to PI3K inhibitors revealed that...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Vora, Sadhna R., Juric, Dejan, Kim, Nayoon, Mino-Kenudson, Mari, Huynh, Tiffany, Costa, Carlotta, Lockerman, Elizabeth L., Pollack, Sarah F., Liu, Manway, Li, Xiaoyan, Lehar, Joseph, Wiesmann, Marion, Wartmann, Markus, Chen, Yan, Cao, Z. Alexander, Pinzon-Ortiz, Maria, Kim, Sunkyu, Schlegel, Robert, Huang, Alan, Engelman, Jeffrey A.
פורמט: Artigo
שפה:Inglês
יצא לאור: 2014
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4155598/
https://ncbi.nlm.nih.gov/pubmed/25002028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccr.2014.05.020
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים